You are here

AETC National Coordinating Resource Center

François-Xavier Bagnoud Center
School of Nursing, Rutgers, The State University of New Jersey
65 Bergen Street, 8th floor
Newark, NJ 07101

phone: (973) 972-5141
fax: (973) 972-0397
email: [email protected]

The AETC National Coordinating Resource Center provides education, training, and capacity building resources for the AETC Program to support the mission to offer timely, high quality, state-of-the-science information to healthcare professionals working with existing and emerging populations affected by HIV.

Resources: 35

Titlesort descending Publish Date Review Date
Assisting HIV Patients Returning to Mexico and Central America / Asistiendo a los Pacientes que Regresan a México y Centroamérica 10/1/2020
Barriers to Curing Hepatitis C Virus among Coinfected People with HIV Infographic 3/22/2017
Brand and Generic Names of ARVs in the United States and Mexico 6/20/2018
Conducting a Primary or Acute Care HIV Telemedicine Visit 6/9/2020
COVID-19 Resources for HIV Providers 3/20/2020 7/1/2021
COVID-19, HIV, and Housing Instability 12/29/2020
Direct-acting Antiviral (DAA) Prior Authorization Letter Templates 6/10/2020
Evaluating AETC NCRC Partnerships for Impact 4/15/2019
Federal COVID-19 Resources 10/14/2020
Federal Training Centers Collaborative (FTCC) Virtual Learning Session Materials 3/25/2021
Flyer: Hepatitis C Screening and Treatment in People with HIV 6/29/2018 11/19/2019
Hep C Free Postcard 5/31/2018 11/29/2019
HHS Adult ART Guidelines: HIV and ART in Older People 1/31/2020
HHS Adult ART Guidelines: Initial Therapy 6/10/2021
HHS Adult ART Guidelines: Transgender People with HIV 1/31/2020
HHS Adult ART Guidelines: Treatment-Experienced Patients 6/10/2021
HIV & SARS-CoV-2 Webinar Series 12/7/2020
HIV Epidemic Rapid Response Toolkit 6/10/2019
HIV/HCV Co-infection: An AETC National Curriculum 7/13/2017 12/29/2019
Immediate ART Initiation & Restart: Guide for Clinicians 6/10/2021
Integrating Behavioral Health into Primary HIV Care — Covering the Bases 8/16/2021
Integrating Mental Health and Substance Use Care into HIV Primary Care Toolkit 6/2/2015 5/17/2019
Myths about Providing HCV Treatment to People with HIV with Substance Use Disorder(s) 11/27/2018 7/26/2021
New Pandemic, Old Inequities: Impacts of COVID-19 and HIV on Marginalized Populations 3/26/2021
Non-Occupational Post-Exposure Prophylaxis (nPEP) Toolkit 1/19/2022
Passport to Cure 3/9/2018 11/29/2019
Post COVID Syndrome: An Overview and Approach to Management 4/2/2021
Prescribing nPEP Infographic 1/22/2018 5/18/2021
Prescribing PrEP: A Guide for Healthcare Providers 1/11/2022
Reaching People with HIV in Rural United States 12/6/2021
Resources for Accessibility 7/30/2014 7/20/2018
Results and Response to a 10-State COVID-19 Practice Impact Survey in the Mountain West Region 12/1/2020
Risk, Presentation, Treatment, and Outcomes of COVID-19 in People with HIV 2/9/2021
Ryan White HIV/AIDS Program (RWHAP) Clinical Conference 12/4/2019
Self-care, Resiliency, and Stress Management for Healthcare Providers 1/14/2021 5/18/2021

Articles: 48

  • HIV Meds Updates - TANGO and SALSA Studies: Switch to DTG/3TC from 3-Drug ART

    Susa Coffey's picture

    TANGO is a randomized open-label study in which subjects with virologic suppression on standard 3-drug TAF-based ART either switched to the 2-drug regimen of dolutegravir (DTG)/lamivudine (3TC) n = 369) or continued their baseline ART (n = 372). Previously published data...

  • HIV Meds Updates: Long-acting Injectable Therapy: Lenacapavir

    Susa Coffey's picture

    Lenacapavir (LEN) is a novel investigational long-acting injectable ARV that is administered every 6 months by subcutaneous (SC) injection. It is an HIV-1 capsid inhibitor that acts at several points in the HIV life cycle. As a novel class, has full activity against viruses with resistance to...

  • HIV Meds Updates - Long-acting Injectable Therapy: Cabotegravir + Rilpivirine

    Susa Coffey's picture

    The FLAIR study evaluated the efficacy and safety of the long-acting injectable regimen of cabotegravir (CAB) + rilpivirine (RPV) in previously ART-naïve individuals who switched to CAB+RPV after viral suppression on a standard 3-drug oral regimen (dolutegravir [DTG]/ABC/3TC). At both 48 weeks (...

  • HIV Care Tools – A New Resource for Ending the HIV Epidemic

    Judy Collins's picture

    HIV Care Tools combines the most up-to-date, HIV screening, prevention, and care resources in one mobile app, to provide access to essential point-of-care information and expert clinical support with just one touch.

    HIV Care Tools is for busy clinicians from novice-to-expert, clinic...

  • HIV-related Journal Articles by AETC-Affiliated Researchers and Faculty, 2019-2020

    Judy Collins's picture

    We close out 2020 by recognizing the productivity of the AETC community despite this year’s challenges and setbacks. In addition to restructuring and reimagining their clinical settings and AETC-related programming due to the COVID-19 pandemic, AETC members were also researching and...

  • Long-acting Injectable PrEP: Cabotegravir

    Susa Coffey's picture

    A long-acting formulation of the investigational integrase inhibitor cabotegravir (CAB) is being studied as a single agent for HIV prevention. (CAB also has been studied, in combination with long-acting rilpivirine, as treatment for people with HIV, see Long-Acting Injectable ART: Cabotegravir...

  • New ARV Approval - Fostemsavir

    Susa Coffey's picture

    In July 2020, the U.S. Food and Drug Administration approved fostemsavir (FTR) for treatment of people with multi-drug resistant HIV-1 whose current ARV regimen is failing because of resistance, intolerance, or safety issues. FTR is a novel attachment inhibitor that binds the HIV envelope...

  • Safety of Dolutegravir at Conception: Updated Data

    Susa Coffey's picture

    In 2018, initial results from the Tsepamo study of birth outcomes in Botswanan women treated with ART during pregnancy raised questions about the safety of dolutegravir (DTG) when given at the time of conception or very early in pregnancy. Specifically, an early interim analysis found a higher...

  • AETC Representation at the 2020 National Ryan White Conference on HIV Care & Treatment

    Judy Collins's picture

    Below is the preliminary schedule of AETC Program sessions and poster presentations planned for the 2020 National Ryan White Conference on HIV Care & Treatment. The AETC National Coordinating Resource Center will also be exhibiting, representing the AETC Program's training materials,...

  • Long-Acting Injectable ART: Cabotegravir + Rilpivirine

    Susa Coffey's picture

    At CROI 2019, investigators presented 48-week results from the Phase 3 international multisite ATLAS and FLAIR studies of long-acting 2-drug injectable therapy. The study regimen consisted of the integrase inhibitor cabotegravir (CAB) plus the NNRTI rilpivirine (RPV), both given every 4 weeks as...


    Susa Coffey's picture

    TDF/FTC (Truvada) is the only ARV combination currently approved by the FDA for use as preexposure prophylaxis (PrEP). The multinational Phase 3 DISCOVER Study compared the efficacy and safety of TAF/FTC (Descovy) with TDF/FTC, in HIV-uninfected cisgender MSM and transgender women at high risk...

  • FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine

    Susa Coffey's picture

    In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients. The approval specifies that DTG/3TC is...

  • Rapid ART Start

    Susa Coffey's picture

    The International AIDS Society (IAS)-USA recently released its 2018 HIV treatment and prevention recommendations. The document is particularly notable for its discussion of "When to Start ART."

    The IAS-USA recommends "rapid" or immediate start of ART upon diagnosis of HIV, stating that...

  • Doravirine--New NNRTI Approved by FDA

    Susa Coffey's picture

    The U.S. Food and Drug Administration has approved the NNRTI doravirine for use in initial HIV therapy. FDA approval was based on 48-week results of 2 Phase III studies in treatment-naive persons that showed doravirine + 2 NRTIs resulted in similar rates of viral suppression at 48 weeks as...

  • Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects

    Jennifer Cocohoba's picture

    Integrase inhibitors have become primary treatment for most people with HIV; however, the impact of newer integrase inhibitors on pregnancy outcomes has not been well described. Researchers for the observational Tsepamo study have been examining birth outcomes in Botswanan women treated with...

  • Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy

    Jennifer Cocohoba's picture

    Although DTG currently is not a desirable medication for women to take pre-conception (see Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects), findings from the DolPHIN study suggest that it may be a very useful agent for women who start ART during late pregnancy....

  • Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women

    Jennifer Cocohoba's picture

    Two pharmacokinetic studies from AIDS 2018 help elucidate the disposition of tenofovir alafenamide (TAF) and cobicistat-boosted darunavir during pregnancy.

    The IMPAACT P1026s study examined plasma concentrations of TAF with and without cobicistat in 43 pregnant women. For women taking...

  • TargetHIV: New Name, New Look

    Nicolé H. Mandel's picture

    It's easier than ever to stay on target. The Health Resources and Services Administration's (HRSA) Ryan White HIV/AIDS Program (RWHAP) technical assistance (TA) and training website has undergone a major update to make it easier for users to access tools and materials for the RWHAP. The...

  • U=U in PARTNER2 Study of MSM

    Susa Coffey's picture

    PARTNER1, whose results were reported last year,(1) was one of the studies that supported current efforts to promote the growing scientific consensus supporting "Treatment as Prevention" (TasP) or Undetectable = Untransmittable (U=U).

    PARTNER1 evaluated HIV transmission risk in a...

  • Dolutegravir + 3TC in Initial Therapy

    Susa Coffey's picture

    As we have commented in the past, initial ARV regimens consisting of 2 drugs tend to perform poorly in comparison with currently recommended 3-drug regimens. Yet, given toxicity concerns about some ARVs (particularly about tenofovir DF and abacavir) and cost concerns about 3-drug regimens, the...

  • Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study

    Susa Coffey's picture

    The U.S. Food and Drug Administration has given approval to a coformulation of darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (TAF) 10 mg, to be marketed under the brand name Symtuza. DRV/COBI/FTC/TAF constitutes a complete regimen for patients with susceptible HIV...

  • Possible Safety Issue with Dolutegravir during Pregnancy: Reports of Neural Tube Defects

    Susa Coffey's picture

    On May 18, 2018, the U.S. Food and Drug Administration and the World Health Organization announced that cases of neural tube defects have been reported in babies of women with HIV who were on treatment with dolutegravir at the time of conception and during early pregnancy. The...

  • Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)

    Jennifer Cocohoba's picture

    Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain...

  • Bictegravir Approved for Initial ART, in Combination with TAF/FTC

    Susa Coffey's picture

    Bictegravir (BIC), a new integrase inhibitor, was recently approved by the FDA for use in a single-pill coformulation with TAF/FTC (brand name: Biktarvy) as initial therapy and as a switch regimen for patients who are already on a suppressive ART regimen and who have no history of...

  • Ibalizumab Approved for Persons with Multidrug Resistant HIV

    Susa Coffey's picture

    Ibalizumab (TNX-355), an entry inhibitor, has been approved by the FDA for use in persons with an extensive ARV treatment history and multidrug resistant HIV who are on a failing ARV regimen. Ibalizumab (trade name: Trogarzo) is a monoclonal antibody that binds the CD4 receptor and blocks HIV...

  • Bictegravir/TAF/FTC in Women

    Susa Coffey's picture

    The single-pill combination of bictegravir (BIC) with tenofovir alafenamide (TAF) and emtricitabine (FTC) has been shown in four Phase III trials to be effective as initial therapy.Also as a switch regimen in patients with stably suppressed HIV RNA and no resistance to BIC, TAF,...

  • Immediate ART Initiation Improves Time to Viral Suppression

    Susa Coffey's picture

    The availability of ART immediately after the diagnosis of HIV offers many possible benefits, including earlier engagement in care and earlier HIV suppression, which may result in personal and public health benefits. Based on randomized clinical trials done in developing-world settings, the...

  • Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study

    Susa Coffey's picture

    The EMERALD Study is a Phase III, open-label, noninferiority study in which 1,141 patients with stable HIV suppression on a regimen comprising a boosted protease inhibitor plus TDF/FTC were randomized (2:1) to either switch to an investigational single-tablet regimen containing...

  • Naltrexone Improves Virologic Suppression

    Susa Coffey's picture

    Release from correctional settings is a high-stakes time for persons with HIV, as it is for those with other health issues. People with substance use disorders often relapse, and those with HIV often stop ART and do not engage in HIV care, increasing the risk of declines in...

  • Undetectable = Untransmittable: Effective HIV Treatment Prevents HIV Transmission

    Susa Coffey's picture

    In September 2017, the U.S. Centers for Disease Control and Prevention (CDC) officially recognized that suppressing HIV through antiretroviral therapy (ART) prevents sexual transmission of HIV. In a "Dear Colleague" letter, CDC officials said, "people who take ART daily as...

  • Doravirine in Initial Therapy: DRIVE-AHEAD Study

    Susa Coffey's picture

    Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the...

  • On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen

    Jennifer Cocohoba's picture

    The EMERALD Study is a Phase 3 randomized (2:1), open-label, noninferiority study examining the strategy of switching patients with suppressed HIV RNA on a regimen consisting of a boosted protease inhibitor plus tenofovir disoproxil fumarate (TDF)/emtricitabine to an investigational single-...

  • Bictegravir in Initial Therapy

    Susa Coffey's picture

    Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...

  • CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment

    Susa Coffey's picture

    Doravirine is an investigational NNRTI that is active in vitro against many common NNRTI resistance mutations (including K103N, Y181C, and E138K). It is given once daily, has no food restrictions, and can be given with acid-blocking medications. In a Phase 2 study of treatment-...

  • CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison

    Susa Coffey's picture


    Bictegravir is an investigational integrase inhibitor that is dosed once daily, unboosted. It is active in vitro against many viruses with integrase resistance mutations. A Phase 2 double-blind placebo-controlled study randomized treatment-naive...

  • CROI 2017: Dolutegravir in 2-Drug Simplification Studies

    Susa Coffey's picture

    In recent years, a number of studies have evaluated 2-drug or even 1-drug ARV regimens, either in initial therapy or in switch regimens for patients with virologic suppression on 3-drug therapy. In general, these have not been as successful in achieving or maintaining virologic suppression as...

  • CROI 2017: Failure of Dolutegravir Monotherapy

    Susa Coffey's picture

    Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...

  • HIV Meds Update - RAPID: Immediate ART Initiation

    Susa Coffey's picture

    This publication presents the results of San Francisco General Hospital's Ward 86 pilot study of immediate ART initiation. This RAPID program systematically offered ART to patients upon diagnosis of HIV; patients were referred from HIV testing sites in San Francisco. Of the 39 patients who...

  • HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk - also a Word on HPTN 052

    Susa Coffey's picture

    The PARTNER Study, a multisite European study, evaluated rates of HIV transmissions within serodifferent heterosexual and MSM couples (n = 548 and n = 340, respectively, contributed eligible data). The HIV-positive partners were on ART with HIV RNA levels of <200 copies/mL, and the couples...

  • HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA

    Susa Coffey's picture

    We know that very early treatment in acute HIV infection decreases HIV RNA; this study shows it also greatly decreases proviral DNA (and reservoir size). Researchers investigated 2 small cohorts of patients in Thailand with acute (and very early) HIV infection, 1 untreated and 1 treated with ART...

  • HIV Meds Update: PrEP Uptake by Sex, Race, and Age

    Susa Coffey's picture

    At the ASM Microbe meeting in June, researchers from Gilead Sciences presented data on use of TDF/FTC (Truvada) PrEP in the United States according to sex and race. They evaluated national pharmacy databases to identify prescriptions of TDF/FTC given for PrEP between January 2012 and September...

  • Use of Dolutegravir in Dialysis

    Jennifer Cocohoba's picture

    Dolutegravir has several characteristics that, in theory, suggest it will not be significantly removed by dialysis: It has a large apparent volume of distribution (17.4 L) and is highly protein bound (98.9%). A small study of 5 HIV-infected patients with end-stage renal disease...

  • PrEP: Bone Density Improves after Stopping TDF/FTC

    Susa Coffey's picture

    Tenofovir disoproxil fumarate (TDF) may cause decreases in bone mineral density (BMD). In both HIV-infected patients treated with TDF-containing ARV regimens, and in HIV-uninfected persons who use it for PrEP. A substudy of the large iPrEx trial of TDF/FTC PrEP in MSM and transgender women...

  • Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy

    Jennifer Cocohoba's picture

    Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...

  • Switching from TDF/FTC to TAF/FTC

    Susa Coffey's picture

    Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...

  • Tissue Levels of TAF: Too Low for PrEP?

    Susa Coffey's picture

    There was a pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February. It evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue. Also in anogenital fluid samples after administration of oral...

  • Tips for Successful Linkage to Care

    Elizabeth I. Lazo's picture

    I would like to start this new year introducing myself to the AIDS Education and Training Center (AETC) community.  I had the pleasure of joining the AETC National Coordinating Resource Center (NCRC) as a Health Educator in December 2015.  I look forward to using my skill set as a...

  • START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV

    Jennifer Cocohoba's picture

    The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and...